Cargando…

The Efficacy of Bevacizumab in Different Line Chemotherapy for Chinese Patients with Metastatic Colorectal Cancer

Objective: To evaluate the effect of bevacizumab in different lines for Chinese patients with metastatic colorectal cancer (mCRC). Methods: Patients of mCRC treated with bevacizumab or not at Sun Yat-sen University Cancer Center from 2007 to 2013 were recruited as study and control group. Endpoints...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yin, Chenxi, Ma, Gang, Rong, Yuming, Kong, Pengfei, Yang, Qiong, Jiang, Chang, Liao, Fangxin, Zhang, Bei, He, Wenzhuo, Xia, Liangping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5039375/ https://www.ncbi.nlm.nih.gov/pubmed/27698931 http://dx.doi.org/10.7150/jca.15802

Ejemplares similares

Bevacizumab plus chemotherapy as third- or later-line therapy in patients with heavily treated metastatic colorectal cancer
por: Yang, Qiong, et al.
Publicado: (2015)

Initial LDH level can predict the survival benefit from bevacizumab in the first-line setting in Chinese patients with metastatic colorectal cancer
por: Yin, Chenxi, et al.
Publicado: (2014)

The Prognostic and Predictive Value of Carbohydrate Antigen 19-9 in Metastatic Colorectal Cancer Patients with First Line Bevacizumab Containing Chemotherapy
por: Jiang, Chang, et al.
Publicado: (2017)

Longterm effects of palliative local treatment of incurable metastatic lesions in colorectal cancer patients
por: Yang, Qiong, et al.
Publicado: (2016)

A high LDL-C to HDL-C ratio predicts poor prognosis for initially metastatic colorectal cancer patients with elevations in LDL-C
por: Liao, Fangxin, et al.
Publicado: (2015)

First-line cetuximab improves the efficacy of subsequent bevacizumab for RAS wild-type left-sided metastatic colorectal cancer: an observational retrospective study
por: Liu, Shousheng, et al.
Publicado: (2020)

Impact of Serum Apolipoprotein A-I on Prognosis and Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer: a Propensity Score-Matched Analysis()
por: Quan, Qi, et al.
Publicado: (2017)

Primary Tumor Location as a Predictive Factor for First-line Bevacizumab Effectiveness in Metastatic Colorectal Cancer Patients
por: He, Wen-Zhuo, et al.
Publicado: (2017)

Efficacy of Adding Bevacizumab in the First-Line Chemotherapy of Metastatic Colorectal Cancer: Evidence from Seven Randomized Clinical Trials
por: Chen, Yan-xian, et al.
Publicado: (2014)

Glasgow PrognosticScore as a Predictor of BevacizumabEfficacy in the First-line Treatment with Metastatic Colorectal Cancer
por: Huang, Yuanyuan, et al.
Publicado: (2019)

Brain metastases in newly diagnosed colorectal cancer: a population-based study
por: Yang, Lin, et al.
Publicado: (2018)

Efficacy and mechanism of combination of oxaliplatin with PKM2 knockdown in colorectal cancer
por: Yin, Chenxi, et al.
Publicado: (2020)

Effect and safety of bevacizumab-containing chemotherapy treatment in Chinese patients with metastatic colorectal cancer
por: Wu, Qian, et al.
Publicado: (2013)

Second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab for patients with metastatic colorectal cancer
por: Yamamoto, Shun, et al.
Publicado: (2021)

The Effects of Anti-inflammatory Drug Treatment in Gastric Cancer Prevention: an Update of a Meta-analysis
por: Kong, Pengfei, et al.
Publicado: (2016)

Second primary colorectal cancer after the initial primary colorectal cancer
por: Yang, Lin, et al.
Publicado: (2018)

PD-1/PD-L1 inhibitor plus chemotherapy versus bevacizumab plus chemotherapy in first-line treatment for non-squamous non-small-cell lung cancer
por: Yu, Hui, et al.
Publicado: (2021)

The Impact of Bevacizumab and Chemotherapy on Quality of Life in Metastatic Colorectal Cancer Patients
por: Moisuc, Diana Cornelia, et al.
Publicado: (2023)

Comparisons of metastatic patterns of colorectal cancer among patients by age group: a population-based study
por: Yang, Lin, et al.
Publicado: (2018)

Efficacy of bevacizumab and chemotherapy in the first-line treatment of metastatic colorectal cancer: broadening KRAS-focused clinical view
por: Bencsikova, Beatrix, et al.
Publicado: (2015)

Predictive value of prognostic nutritional and systemic immune-inflammation indices for patients with microsatellite instability-high metastatic colorectal cancer receiving immunotherapy
por: Yi, Jiahong, et al.
Publicado: (2023)

Association between Mismatch-repair Genetic variation and the Risk of Multiple Primary Cancers: A Meta-Analysis
por: Kong, Pengfei, et al.
Publicado: (2017)

Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial
por: Guan, Zhong-Zhen, et al.
Publicado: (2011)

Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials
por: Loupakis, Fotios, et al.
Publicado: (2010)

A Non-Interventional Multicenter Study of First-Line Bevacizumab in Combination with Chemotherapy in Patients with Metastatic Colorectal Cancer in Lebanon
por: Temraz, Sally, et al.
Publicado: (2022)

Bevacizumab plus chemotherapy as salvage treatment in chemorefractory patients with metastatic colorectal cancer
por: Geva, Ravit, et al.
Publicado: (2013)

Proximal shift of colorectal cancer with increasing age in different ethnicities
por: Yang, Lin, et al.
Publicado: (2018)

First‐line therapy of bevacizumab plus chemotherapy versus cetuximab plus chemotherapy for metastatic colorectal cancer patients with mucinous adenocarcinoma or mucinous component
por: Zhou, Yu‐Wen, et al.
Publicado: (2021)

Combination of primary tumor location and mismatch repair status guides adjuvant chemotherapy in stage II colon cancer
por: Yang, Lin, et al.
Publicado: (2017)

Tumor microenvironment classification based on T-cell infiltration and PD-L1 in patients with mismatch repair-proficient and -deficient colorectal cancer
por: Liu, Shousheng, et al.
Publicado: (2019)

Establishment of inflammation biomarkers-based nomograms to predict prognosis of advanced colorectal cancer patients based on real world data
por: Guo, Guifang, et al.
Publicado: (2018)

Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer
por: Feliu, J, et al.
Publicado: (2010)

Chemotherapy plus Panitumumab Versus Chemotherapy plus Bevacizumab in Metastatic Colorectal Cancer: A Meta-analysis
por: Li, Zhigui, et al.
Publicado: (2018)

A Review of Clinical Studies and Practical Guide for the Administration of Triplet Chemotherapy Regimens with Bevacizumab in First-line Metastatic Colorectal Cancer
por: Loupakis, Fotios, et al.
Publicado: (2015)

Bevacizumab-based first-line chemotherapy in elderly patients with metastatic colorectal cancer: an individual patient data based meta-analysis
por: Koch, Christine, et al.
Publicado: (2017)

Survival benefit of surgical resection after first-line triplet chemotherapy and bevacizumab in patients with initially unresectable metastatic colorectal cancer
por: Elshenawy, Mahmoud A., et al.
Publicado: (2020)

Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy
por: Österlund, P, et al.
Publicado: (2011)

Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer
por: Loupakis, Fotios, et al.
Publicado: (2018)

Trends in Use and Perceptions About Triplet Chemotherapy Plus Bevacizumab for Metastatic Colorectal Cancer
por: van Nassau, Sietske C., et al.
Publicado: (2021)

Efficacy of third-line therapy using bevacizumab in a patient with metastatic colorectal cancer
por: Gaulin, J., et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_mok15cshaane62ej4cdfu5vtkf